(Source: Merck Canada Inc) 00f0678e-090a-4f9c-a736-8cbc159b1544.pdf News Release FOR IMMEDIATE RELEASE Media Contact: Annick Robinson (438) 837-2550 Investor Contact: Amy Klug (908) 740-1898 Merck Receives Approval of ZEPATIER™ (elbasvir/grazoprevir) in Canada for the Treatment of Chronic Hepatitis C for Patients with Genotype 1, 3, or 4 Infection Following Priority Review ZEPATIER Achieves High Cure Rates* (SVR12) of 95-98% in Broad Range of Patients with Chronic Hepatitis C Infection, Including Those with Compensated Cirrhosis, Renal Impairment of Any Degree and HIV-1/HCV Co-infection Kirkland, QC - February 3, 2016 - Merck (NYSE: MRK), known as MSD outside Canada and the United States,...
↧